Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C, Sirohi B, Bhagwati N, Meller S, Saso R, Mehta J
Leukaemia and Myeloma Units, Royal Marsden Hospital, Surrey, UK.
Blood. 2000 Jun 15;95(12):3683-6.
Incidences of and risk factors for Streptococcus pneumoniae sepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated at a single center between 1973 and 1997. SPS developed in 31 patients a median of 10 months after transplantation (range, 3 to 187 months). The infection was fatal in 7 patients. The probability of SPS developing at 5 and 10 years was 4% and 6%, respectively. Age, sex, diagnosis, and graft versus host disease (GVHD) prophylaxis did not influence the development of SPS. Allogeneic transplantation (10-year probability, 7% vs 3% for nonallogeneic transplants; P =.03) and chronic GVHD (10-year probability, 14% vs 4%; P =.002) were associated with significantly higher risk for SPS. All the episodes of SPS were seen in patients who had undergone allograft or total body irradiation (TBI) (31 of 1202 vs 0 of 127; P =.07). Eight patients were taking regular penicillin prophylaxis at the time of SPS, whereas 23 were not taking any prophylaxis. None of the 7 patients with fatal infections was taking prophylaxis for Pneumococcus. Pneumococcal bacteremia was associated with higher incidences of mortality (6 of 15 vs 1 of 16; P =.04). We conclude that there is a significant long-term risk for pneumococcal infection in patients who have undergone allograft transplantation, especially those with chronic GVHD. Patients who have undergone autograft transplantation after TBI-containing regimens also appear to be at increased risk. These patients should receive lifelong pneumococcus prophylaxis. Consistent with increasing resistance to penicillin, penicillin prophylaxis does not universally prevent SPS, though it may protect against fatal infections. Further studies are required to determine the optimum prophylactic strategy in patients at risk. (Blood. 2000;95:3683-3686)
对1973年至1997年间在单中心接受治疗的1329例患者进行分析,以探讨造血干细胞移植后肺炎链球菌败血症(SPS)的发生率及危险因素。31例患者发生SPS,移植后中位时间为10个月(范围3至187个月)。7例患者感染致死。SPS在5年和10年时发生的概率分别为4%和6%。年龄、性别、诊断及移植物抗宿主病(GVHD)预防措施均不影响SPS的发生。异基因移植(10年概率为7%,非异基因移植为3%;P = 0.03)及慢性GVHD(10年概率为14%,非慢性GVHD为4%;P = 0.002)与SPS的显著高风险相关。所有SPS发作均见于接受同种异体移植或全身照射(TBI)的患者(1202例中有31例,127例中无1例;P = 0.07)。8例患者在发生SPS时正在接受常规青霉素预防,而23例未接受任何预防。7例致死性感染患者中无一例接受肺炎球菌预防。肺炎球菌菌血症与较高的死亡率相关(15例中有6例,16例中有1例;P = 0.04)。我们得出结论,接受同种异体移植的患者,尤其是患有慢性GVHD的患者,存在肺炎球菌感染的显著长期风险。接受含TBI方案自体移植后的患者似乎也有风险增加。这些患者应接受终身肺炎球菌预防。尽管青霉素预防可能预防致死性感染,但与对青霉素耐药性增加一致的是,青霉素预防并不能普遍预防SPS。需要进一步研究以确定高危患者的最佳预防策略。(《血液》。2000年;95:3683 - 3686)